Organon (OGN) said Wednesday it has agreed to acquire Roivant's (ROIV) Dermavant, including its flagship dermatological cream Vtama, for a total consideration of $1.2 billion.
Under the deal, Organon will pay $175 million upfront with $75 million as milestone payment after the US Food and Drug Administration approves Vtama's application for treatment of atopic dermatitis, followed by commercial milestone payments of up to $950 million. The companies expect the FDA to decide on its review in Q4.
The transaction is expected to close in Q4.
Price: 20.22, Change: -0.33, Percent Change: -1.61
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。